Clinical Trial Update: Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating totally neoadjuvant regimen (FOLFOXIRI + short-course radiation + XELOX) in locally advanced rectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• FOLFOXIRI (folinic acid (leucovorin), fluorouracil (5-FU), oxaliplatin, irinotecan)
• XELOX (capecitabine + oxaliplatin)
• short-course radiotherapy (radiation therapy)

Snippet

Sponsor: China Medical University, China | Conditions: Rectal Neoplasms, Drug Therapy | Phase 2 | Status: UNKNOWN